Development of a potent, practical neoantigen vaccine is currently a key objective of immuno-oncology. Oncolytic immunotherapy uniquely generates a potent, patient specific tumor neoantigen vaccine directly in situ in the patient. Replimune aims to provide a highly potent ‘universal’ neoantigen vaccine through it’s approach.
Tumor selective virus replication kills tumors. This releases the full array of neoantigens in an inflamed tumor environment. Both innate and adaptive immune responses are triggered, including through TLR and STING signaling. This provides systemic vaccination and systemic efficacy, and is highly synergistic with immune checkpoint blockade.